Brian Silver, JD

Brian Silver, J.D., has been the Chief Financial Officer at TScan Therapeutics since 2021 and previously served on the board. Prior to joining TScan, Brian served as Freeline Therapeutics’ CFO and Head of Corporate Development. In his two CFO roles Brian led two Nasdaq IPOs and raised over $600 million through private and public financings as well as business development transactions.
Before joining Freeline, Brian was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to that, Brian was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell.

Brian has worked with a range of large and emerging pharmaceutical and biotechnology clients during his 25-year Wall Street career. His investment banking and corporate law advisory experience includes dozens of M&A and financing transactions across all capital markets, including IPOs, follow-ons, high yield, convertible and investment grade debt, as well as royalty financings. His M&A experience includes sell side and buy side transactions and leveraged buyouts, as well as reverse mergers and corporate restructurings.
Brian received a B.A. with honors from Harvard College and a J.D. with honors from the University of Chicago Law School.
Speaking In
3:30 PM - 4:30 PM
Monday, June 5
In today’s turbulent market backdrop, both life science companies and investors are required to…